ReviewFrontiers in bioengineering and biotechnology2025
Natural polymers in diabetes management: formulation prospects of
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Smart Hydrogel Design to 4D-Printed Scaffolds: Emerging Paradigms in Precision Drug Delivery and Regenerative Wound Therapy.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a long-term metabolic disorder distinguished by hyperglycemia with the limitation of severe complications unless treated effectively. Metformin is the first-line agent for treating diabetes type 2 but has the drawback of a short half-life, incomplete absorption and is associated with gastrointestinal side effects requiring multiple times a day dosing. Sustained release (SR) formulations have been explored for the delivery of metformin while prolonging plasma levels, decreasing the frequency of dosing and increasing adherence improve patient compliance and outcomes related to diabetes. Some natural polymers have attracted attention as excipients for SR systems because they are biocompatible, biodegradable, and cost-effective. Specifically,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.